Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 16;11(10):2807.
doi: 10.3390/jcm11102807.

Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives

Ewa Robak  1 , Tadeusz Robak  2   3
Affiliations
Review

Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives

Ewa Robak et al. J Clin Med. .

Abstract

The use of Bruton's tyrosine kinase (BTK) inhibitors has changed the management of patients with B-cell lymphoid malignancies. BTK is an important molecule that interconnects B-cell antigen receptor (BCR) signaling. BTK inhibitors (BTKis) are classified into three categories, namely covalent irreversible inhibitors, covalent reversible inhibitors, and non-covalent reversible inhibitors. Ibrutinib is the first covalent, irreversible BTK inhibitor approved in 2013 as a breakthrough therapy for chronic lymphocytic leukemia patients. Subsequently, two other covalent, irreversible, second-generation BTKis, acalabrutinib and zanubrutinib, have been developed for lymphoid malignancies to reduce the ibrutinib-mediated adverse effects. More recently, irreversible and reversible BTKis have been under development for immune-mediated diseases, including autoimmune hemolytic anemia, immune thrombocytopenia, multiple sclerosis, pemphigus vulgaris, atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's disease, and chronic spontaneous urticaria, among others. This review article summarizes the preclinical and clinical evidence supporting the role of BTKis in various autoimmune, allergic, and inflammatory conditions.

Keywords: AIHA; BTK inhibitor; ITP; IgG4-related disease; atopic dermatitis; chronic spontaneous urticaria; multiple sclerosis; pemphigus vulgaris; rheumatoid arthritis; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. Writing assistance was not utilized in the production of this manuscript.

References

    1. Bruton O.C. Agammaglobulinemia. Pediatrics. 1952;9:722–728. doi: 10.1542/peds.9.6.722. - DOI - PubMed
    1. Conley M.E., Brown P., Pickard A.R., Buckley R.H., Miller D.S., Raskind W.H., Singer J.W., Fialkow P.J. Expression of the gene defect in X-linked agammaglobulinemia. N. Engl. J. Med. 1986;315:564–567. doi: 10.1056/NEJM198608283150907. - DOI - PubMed
    1. Vetrie D., Vořechovský I., Sideras P., Holland J., Davies A., Flinter F., Hammarström L., Kinnon C., Levinsky R., Bobrow M., et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361:226–233. doi: 10.1038/361226a0. - DOI - PubMed
    1. Satterthwaite A.B., Witte O.N. The role of Bruton’s Tyrosine Kinase in B-cell development and function: A genetic perspective. Immunol. Rev. 2000;175:120–127. doi: 10.1111/j.1600-065X.2000.imr017504.x. - DOI - PubMed
    1. Brullo C., Villa C., Tasso B., Russo E., Spallarossa A. Btk inhibitors: A medicinal chemistry and drug delivery perspective. Int. J. Mol. Sci. 2021;22:7641. doi: 10.3390/ijms22147641. - DOI - PMC - PubMed

LinkOut - more resources